1. Home
  2. PRAA vs AUTL Comparison

PRAA vs AUTL Comparison

Compare PRAA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PRA Group Inc.

PRAA

PRA Group Inc.

HOLD

Current Price

$20.11

Market Cap

705.9M

Sector

Finance

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.95

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAA
AUTL
Founded
1996
2014
Country
United States
United Kingdom
Employees
170
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
705.9M
596.2M
IPO Year
2002
2025

Fundamental Metrics

Financial Performance
Metric
PRAA
AUTL
Price
$20.11
$1.95
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$24.50
$8.50
AVG Volume (30 Days)
346.4K
1.4M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.24
N/A
Revenue
$1,201,837,000.00
$10,120,000.00
Revenue This Year
$2.01
$80.32
Revenue Next Year
$2.53
$53.96
P/E Ratio
$9.19
N/A
Revenue Growth
7.83
496.00
52 Week Low
$10.25
$1.18
52 Week High
$22.55
$2.58

Technical Indicators

Market Signals
Indicator
PRAA
AUTL
Relative Strength Index (RSI) 56.37 N/A
Support Level $16.53 N/A
Resistance Level $21.49 N/A
Average True Range (ATR) 0.81 0.00
MACD 0.10 0.00
Stochastic Oscillator 59.58 0.00

Price Performance

Historical Comparison
PRAA
AUTL

About PRAA PRA Group Inc.

PRA Group Inc is a specialty finance company engaged in the purchase, collection, and management of nonperforming loan portfolios. The majority of the loans it purchases are from credit originators who have chosen not to pursue, or have been unsuccessful in collecting, the full balance owed to them (Core accounts). To a lesser extent, the company also purchases loans in situations where the customer is involved in a bankruptcy or similar proceeding (Insolvency accounts). As part of an ancillary business, it also purchases and provides fee-based services for class action claims recoveries in the U.S. The company has two operating and reportable segments, comprised of its U.S. and European businesses. The majority of its revenue is generated from the United States.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: